CompletedNot Applicable

Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.

United States206 participantsStarted 2019-01-01

Plain-language summary

This is a retrospective chart review that will measure the impact on outcomes in septic shock patients who were resuscitated with a novel combination of medicines called iHAT (intravenous hydrocortisone -ascorbic acid-thiamine). Septic shock patients treated with this combination of drugs over the past two years will be compared with similar, concurrent septic shock patients who were not treated with this drug given that adoption of this therapy has been variable.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Admitting Provider in the ICU Patient database must be on the Critical Care Service * Primary diagnosis of sepsis listed in the ICU Patient Database * Requirement for vasopressors within 24 hours of admission * If outside transfer, transfer to TLC occurred within 24 hours of initial presentation * Patient remained on Critical Care service for a minimum of 48 hours * If treated with iHAT, iHAT started within 36 hours of admission * No transition to comfort care occurred within the first 24 hours Exclusion Criteria: * patients requiring surgical intervention for source control * patients transitioned to comfort measures only within 24 hours of admission

What they're measuring

Duration of Vasopressors

Timeframe: At study conclusion, up to 3 months

Trial details

NCT IDNCT03913468

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-12-01

View on ClinicalTrials.gov More Septic Shock trials